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Objectives: Antisynthetase syndrome (ASS) is characterized by autoantibodies to aminoacyl-
tRNA synthetases (anti-synthetase) and it is frequently associated with interstitial lung
disease. The purpose of this study was to elucidate the prevalence and characteristics of
the anti-synthetase positive subpopulation among idiopathic interstitial pneumonias (IIPs)
and to clarify the importance of screening for these antibodies.
Methods: A retrospective study was performed in 198 consecutive cases with IIPs. Screening
for six anti-synthetase antibodies was performed in all cases. Clinical profiles of all cases were
compared with reference to the presence of anti-synthetase. High-resolution computed
tomography (HRCT) findings of anti-synthetase positive cases were also analyzed.of RehabilitationMedicine/Respiratory Medicine, Kyoto University Hospital, 54 Shogoin Kawahara-cho,
81 75 751 3850; fax: þ81 75 751 4643.
-u.ac.jp (T. Handa).
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Antisynthetase syndrome in IIPs 1239Results: 13 cases (6.6%) were positive for anti-synthetase. Anti-EJ was most prevalent, fol-
lowed by anti-PL-12. Onset ages of anti-synthetase positive cases were younger than those
of anti-synthetase negative cases. Extrapulmonary features of ASS were absent in 6 anti-
synthetase positive cases (46.2%). Histologically, among 5 UIP with lymphoid follicles and 11
NSIP cases, the prevalence of anti-synthetase positive cases was 8/16 (50%). On HRCT, ground
glass opacity and traction bronchiectasis were the major findings in anti-synthetase positive
cases, while honeycombing was absent.
Conclusions: Anti-synthetase positive cases were not rare among IIPs. Anti-synthetase should
be screened for in IIPs, especially in pathological NSIP or UIP with lymphoid follicles. These
patients should be screened for anti-synthetase even if no suggestive extrapulmonary manifes-
tation exists.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Interstitial lung disease (ILD) is caused by both known and
unknown etiologies, and idiopathic interstitial pneumonias
(IIPs) are the most prevalent type of ILD.1 Connective tissue
disease (CTD) affects a wide variety of organs with the
incidence of pulmonary involvement ranging from 19 to
67%.2 A thorough etiological work-up of CTD and its related
conditions is essential in clinical practice for ILD. Difficult-
to-diagnose cases exist when they have an incomplete form
of CTD that cannot be categorized as CTD using a range of
specific criteria. These cases are categorized as idiopathic,
or sometimes unclassifiable.
The aminoacyl-tRNA synthetases are a family of enzymes,
each of which catalyses the formation of aminoacyl-tRNA
from a specific amino acid and its cognate tRNA. Autoanti-
bodies to eight of these synthetases (anti-synthetase) have
been reported and they are defined as myositis-specific
autoantibodies.3 Clinical features that occur in anti-
synthetase positive cases include myositis, ILD, arthritis,
mechanic’s hand and often Raynaud’s phenomenon.
Combination of positive anti-synthetase antibodywith any of
these findings constitutes a distinct syndrome named anti-
synthetase syndrome (ASS).4 The prevalence of anti-
synthetase among PM/DM is 30e40% and characteristics of
anti-synthetase positive populations have been established
in the past, in several myositis-based large cohort studies. In
particular, subpopulations of patients with myositis have
higher rates of ILD when they have anti-synthetase than
those who have not.5 ILD in ASSmay also be indistinguishable
from IIPs when patients have minimal or no myositis. ASS
comprises a distinct disease entity and demonstrates
a generally good response to corticosteroids, though
a number of cases show recurrence after withdrawing or
reducing doses of corticosteroids.6,7 Fisher et al. retro-
spectively assessed 37 patients with IIPs who had some signs
or symptoms indicative of ASS, but were not positive for ANA
or anti-Jo-1 antibody, and found that 9 (24%) patients were
positive for anti-synthetase.8 In this previous study, anti-
synthetase were measured in patients with clinical signs
indicative of ASS, and the decision to perform the test
depended upon each physician; thus the overall prevalence
of anti-synthetase among IIPs was not clarified. The char-
acteristics of patients with anti-synthetase positive IPs are
still unknown together with identification of the population
which should be examined for these antibodies. This studyaimed to investigate the prevalence of an anti-synthetase
positive subpopulation among IIPs. Six anti-synthetase
antibodies were measured and aspects of the clinical,
pathological and radiological features of anti-synthetase
positive cases were investigated to determine which
patients should be screened for these antibodies.
Methods
Patient recruitment
In this study, idiopathic interstitial pneumonia (IIP) was
defined as interstitial pneumonias of unknown cause where
a patient did not fulfill classification criteria for any specific
CTD or vasculitides, and in whom lung diseases were not
potentially caused by drug or occupational-environmental
exposures. Screening for CTD was initially performed by
experienced pulmonologists, and also by rheumatologists in
patients with serological or clinical features suggestive of
CTD.9e16Provisionally, undifferentiated connective tissue
disease (UCTD)17 were not excluded from the study pop-
ulation. In all patients diagnosed with idiopathic interstitial
pneumonias (IIPs) who visited Kyoto University Hospital
from July 2007 through April 2009 and Tenri Hospital, the
tertiary care center from April 2006 through April 2009,
serum samples were consecutively collected and patients
were recruited into this study. The study population
comprised 198 cases with IIPs, 53 with idiopathic pulmonary
fibrosis/usual interstitial pneumonia (IPF/UIP) (30 by
histological diagnosis; 23 by clinical diagnosis), 11 with
nonspecific interstitial pneumonia (NSIP), 3 with histologi-
cally unclassifiable interstitial pneumonia, and 131 with
non-UIP without histology. Written informed consent was
obtained from the participants, and the study was approved
by the Review Board of the Ethical Committee of each
Institute.Data collection
Clinical information was retrospectively obtained from
medical records. The data included patient’s age at onset,
gender, pulmonary or extrapulmonary manifestations
including signs or symptoms of CTD, laboratory data results
including CTD-specific autoantibodies, blood gas analysis,
pulmonary function test results, bronchoalveolar lavage
1240 K. Watanabe et al.fluid (BALF) findings, treatment regimen, definitive diag-
nosis of polymyositis/dermatomyositis (PM/DM) during
observation, and survival. Clinical diagnosis of PM/DM was
made according to the criteria of Bohan and Peter.16Measurement of anti-synthetase
Investigation of anti-synthetase was performed by an RNA
immunoprecipitation procedure (IPP) using sera and HeLa
cell extracts as previously described.7 Briefly, 10 ml of sera
was mixed with protein-A sepharose beads and incubated
with sonicated extracts of HeLa cells. RNAs were extracted
with phenol-chloroform and then resolved in urea-10%
polyacrylamide gel, which was finally visualized with
silver staining (Bio-Rad Laboratories, Hercules, CA, USA).
Each antibody was identified by the mobility and pattern of
tRNA bands (Fig. 1). Among the eight antibodies established
in previous reports, we investigated the following six anti-
bodies; antibodies to histidyl- (Jo-1), threonyl- (PL-7),
alanyl- (PL-12), isoleucyl- (OJ), glycyl- (EJ), and aspar-
aginyl-(KS) tRNA synthetases. The other two antibodies
have only been reported in case presentations, and are
considered to be rare; thus they were not investigated in
this study.3Figure 1 Immunoprecipitation of antibodies to antiaminoacyl-
tRNA synthetases (anti-synthetase). The Figure demonstrates
urea-polyacrylamide gel electrophoresis (PAGE) of immunopre-
cipitates, visualized with silver staining. Anti-synthetase anti-
bodies are indicated in 6 lanes; antibodies to histidyl- (Jo-1),
threonyl- (PL-7), alanyl- (PL-12), isoleucyl- (OJ), glycyl- (EJ), and
asparaginyl-(KS) tRNA synthetases. Each antibody is distinguish-
ableby themobility and pattern of tRNAbands. TNAdenotes totalAssessment of high-resolution computed
tomography (HRCT) findings
Chest high-resolution computed tomography (HRCT) find-
ings were assessed independently by two radiologists (S. N.
and T. K.) who were unaware of the clinical or pathological
data. The lung fields in HRCT were divided into upper,
middle and lower zones at the level of the carina and
inferior pulmonary vein, and findings were assessed sepa-
rately in the three zones of both lungs. The presence or
absence of the following nine findings were reported in
each subdivided lung zone: pleural irregularities and/or
prominent interlobular septa, reticulation, ground glass
opacity, consolidation, subpleural lines, centrilobular
nodular opacity, irregular peribronchovascular thickening,
traction bronchiectasis and bronchiolectasis, honey-
combing.18e20 Initially two readers evaluated the images
and recorded results independently. After the completion
of separate assessment, unified consensus results were
reached through discussion between the two readers.nucleic acids.Statistical analysis
Data were summarized as a median and an interquartile
range. We used the Wilcoxon rank sum test to compare the
numerical variables and chi-square test or Fisher’s exact
test as appropriate to the categorical variables. Interob-
server variances in the initial assessment of HRCT findings
were evaluated using the kappa coefficient for each
finding. KaplaneMeier survival curves were derived for the
study population, and comparisons were made using the log
rank test. We used JMP (version 6, Japanese Edition. SAS
Institute Inc.) in statistical analysis. A p-value of less than
0.05 was considered significant.Results
Prevalence of anti-synthetase and clinical features
Anti-synthetase was found in 13 (6.6%) of 198 cases; anti-EJ
was positive in 6 (3%), anti-PL-12 in 3 (1.5%), and anti-Jo-1,
KS, OJ, and PL-7, one in each case (0.5%). No case exhibited
reactivity to two or more antibodies. Median age at onset
was younger in the anti-synthetase positive group than
in the anti-synthetase negative group (55.0 vs. 67.4 years,
respectively. p < 0.001, Table 1). Significant arthralgia
or joint deformity, and cutaneous manifestations were






Age at the onset (yr) 55.0 [44.5e60.8] 67.4 [60.6e73.2] <0.001y
Female (n; (ratio %)) 6 (46.2) 53 (28.7) 0.20
Smoking history (n) 9 (69.2) 129 (69.7) 0.78
Surgical biopsy for diagnosis (n) 8 (61.5) 36 (19.5) <0.01y
Fever (>38 C) (n) 2 (15.4) 10 (5.4) 0.18
Body weight loss (n) 1 (7.7) 9 (4.9) 0.50
Dyspnea (n) 12 (92.3) 154 (83.2) 0.70
Cough (n) 5 (38.5) 71 (38.4) 1.00
Other respiratory symptoms (n)a 1 (7.7) 9 (4.9) 0.50
Fine crackles (n) 12 (92.3) 167 (90.3) 1.00
Clubbed fingers (n) 1 (7.7) 34 (18.4) 0.47
Arthralgia or joint deformity (n) 2 (15.3) 4 (2.34) < 0.01y
Raynaud’s phenomenon (n) 1 (7.7) 4 (2.2) 0.29
Cutaneous symptoms (n)b 4 (30.8) 3 (1.6) < 0.01y
Oxygen administration (n) 1 (7.7) 18 (9.7) 1.00
Treatment (n) 9 (69.2) 81 (43.8) 0.08
Corticosteroids 1 (7.7) 32 (17.2) 0.06
Corticosteroids plus immunosuppressants 8 (61.5) 49 (26.2)
Immunosuppressants 0 (0.0) 1 (0.5)
No medication 4 (30.8) 105 (56.1)
Duration of the observation (months) 22.8 [17.0e35.1] 39.3 [17.0e65.0] 0.11
Survivor (n) 13 (100) 138 (74.6) 0.04*
Abbreviation: anti-synthetaseZ autoantibody to aminoacyl-tRNA synthetase. Numbers are expressed as median [25%e75% interquartile]
or number of data (percent) Comparison was made by Fisher’s exact test or chi-square test as appropriate; p < 0.05 *, p < 0.01 y.
Treatment regimens included oral corticosteroids, immunosuppressants, and intravenous pulse methylpredonisolone therapy.
a Other respiratory symptoms include chest pain or hemoptysis.
b Cutaneous symptoms include Gottron’s sign and heliotrope purpura.
Antisynthetase syndrome in IIPs 1241frequent in anti-synthetase positive cases (p < 0.01).
However, extrapulmonary features of ASS were absent in 6
anti-synthetase positive cases (46.2%). The number of cases
in treatment tended to be higher in the anti-synthetase
positive group. Survival rate at the end of the observation
period was higher in the anti-synthetase positive group than
in the anti-synthetase negative group (pZ 0.04); however,
survival curves did not reveal a significant difference
between the two groups when analyzed with the log rank
test (p Z 0.22). All the NSIP survived during the study
period regardless of anti-synthetase status; thus survival
differences between anti-synthetase positive and negative
NSIP were not analyzed. No case was diagnosed with PM/DM
during the median observation period of 37.8 months (range
17.0e64.6) regardless of the results for anti-synthetase.
Numbers of patients who met the criteria of UCTD in anti-
synthetase positive and negative groups were 6 of 13 and
21 of 185, respectively. If patients with UCTD were
excluded, the prevalence of anti-synthetase was 7 of 171
(4.1%).
Laboratory data, physiological measurements and
BAL findings
In the anti-synthetase positive group, erythrocyte sedi-
mentation rate (ESR) was significantly higher, and positive
results for rheumatoid factor (RF) and antieSSeA/Ro were
more frequently seen when compared with the anti-synthetase negative group (Table 2). RF and anti-SSA/Ro
were each concomitant with anti-synthetase in 4 cases
(Table 2). There was no difference in the frequencies of
other CTD-specific autoantibodies between ARS-Ab positive
and negative groups (data not shown). The partial pressure
of arterial oxygen (PaO2) was significantly higher in the
anti-synthetase positive group than in the anti-synthetase
negative group (p Z 0.04). The ratio of CD4þ to CD8þ T
lymphocytes in the BAL fluids was predominantly <1 in the
anti-synthetase positive group and >1 in the anti-
synthetase negative group (p < 0.01), though the differ-
ences in differential cell counts were not statistically
significant.
Pathological classification and findings
Biopsy specimens were obtained from 44 patients in this
study; 8 were from anti-synthetase positive patients and 36
were from anti-synthetase negative patients. The numbers
of patients who were diagnosed with NSIP and UIP were 11
and 30 respectively. The NSIP pattern was the most
predominant (6/8, 75%) in the anti-synthetase positive
group. (Table 3). Lymphoid follicles were observed in 7 of 8
cases (87.5%). Fig. 2 illustrates a typical case in the anti-
synthetase positive group: observation of a pathological
NSIP pattern with lymphoid follicles. Two cases in the anti-
synthetase positive group were classified as pathological
UIP pattern. While temporal heterogeneity, microscopic






WBC (/ml) 7300 [5850e12200] 7000 [5700e8600] 0.33
ESR (mm/hr) 48.0 [33.0e67.0] 22.0 [12.0e41.5] 0.02*
CRP (mg/dl) 0.9 [0.3e1.6] 0.2 [0.0e0.8] 0.03*
CPKa (IU/L) 67 [39.3e113] 90 [60e121] 0.24
ALD (IU/L) 5.6 [4.0e8.6] 4.8 [3.7e6.1] 0.27
LDH (IU/L) 255 [219e342] 233 [198e275] 0.17
ANA(>x40) (n) 7/12 (58.3%) 74/174 (42.5%) 0.37
RF(>x15) (n) 4/8 (50.0%) 23/135 (17.0%) 0.04*
AntieSSeA/Ro (>15.6) (n) 4/11 (36.4%) 8/129 (6.2%) <0.01y
AntieSSeB/La (>10.0) (n) 1/11 (9.1%) 3/130 (2.3%) 0.28
PaCO2 (mmHg) 41.7 [36.8e44.6] 41.4 [38.4e44.4] 0.70
PaO2 (mmHg) 85.4 [81.7e90.7] 78.1 [69.6e87.4] 0.04*
% VC (%) 76.7 [63.5e100.7] 87.9 [71.2e101.5] 0.40
% FVC (%) 74.9 [62.6e95.9] 87.6 [68.5e99.9] 0.32
% TLC (%) 72.7 [62.1e90.8] 70.0 [57.3e82.3] 0.54
% RV (%) 79.6 [71.9e92.5] 67.9 [51.0e87.6] 0.07
% Dlco (%) 51.9 [35.8e76.0] 49.8 [37.0e62.6] 0.70
BALF findingsb (n Z 9) (n Z 99)
Total cell count (/ml) 210 [123e293] 200 [100e400] 0.62
Neutrophil (%) 4.0 [0.3e8.0] 6.0 [3.0e14.0] 0.15
Lymphocyte (%) 20.0 [14.3e51.8] 15.5 [6.7e34.8] 0.14
Macrophage (%) 61.5 [35.0e79.3] 67.0 [40.5e82.0] 0.75
Eosinophil (%) 2.0 [1.1e7.3] 3.0 [0.5e5.0] 0.71
CD4/CD8 <1 (n) 7 (77.8) 30 (30.9) <0.01y
Abbreviations: ALD Z aldolase; ANA Z antinuclear antibody; anti-synthetase Z autoantibody to aminoacyl-tRNA synthetase;
BALF Z bronchioalveolar lavage fluid; CPK Z creatine phosphokinase; CRP Z C-reactive protein; Dlco Z diffusion capacity; Dlco/
VA Z diffusion capacity per ESR Z erythrocyte sedimentation rate; FVC Z forced vital capacity; LDH Z lactate dehydrogenase;
PaCO2Z partial pressure of arterial carbon dioxide; PaO2Z partial pressure of arterial oxygen; RFZ rheumatoid factor; RVZ residual
volume; TLC Z total lung capacity; VA Z alveolar ventilation; VC Z vital capacity; WBC Z white blood cell count. Numbers are
expressed as median [25%e75% interquartile] or number of data (percent). Comparison was made by Fisher’s exact test; p < 0.05 *,
p < 0.01 y.
a Normal range of CPK is 35e141(IU/L).
b Number of patients: 9 in anti-synthetase positive and 99 in anti-synthetase negative patients.
1242 K. Watanabe et al.honeycombing, and subpleural dense fibrosis suggested
a UIP pattern (Fig. 3a), the observed moderate cellular
infiltrate was different from a typical UIP (Fig. 3b). Histo-
logical UIP with lymphoid follicles were diagnosed in a total
of 5 cases, and 2 were positive for the antibody. Therefore,
among patients with NSIP or histological UIP with lymphoid
follicles, the prevalence of anti-synthetase antibody was 8/
16 (50%).
HRCT findings in the anti-synthetase positive group
HRCT findings in anti-synthetase positive cases are shown in
Table 4. Interobserver variability (k coefficient) ranged
from 0.60 to 1.0. Abnormal findings were distributed
predominantly in lower lung fields. Pleural irregularities
and/or prominent interlobular septa, reticulation, ground
glass opacity, and traction bronchiectasis or bronchio-
lectasis were observed in more than 80% of cases. Consol-
idation, subpleural lines, and irregular peribronchovascular
thickening were observed predominantly in lower lung
fields in 50% of cases. Honeycombing was not seen in any
case. Even in cases with pathological diagnosis of UIPpattern, radiological findings did not follow a typical IPF/
UIP pattern (Fig. 3c). Centrilobular nodular opacity was
found in a substantial number of anti-synthetase positive
cases (Fig. 4).
Discussion
We have demonstrated the prevalence of anti-synthetase
among a substantial number of patients with IIPs to be 6.6%
(13 of 198 cases). Measurements were carried out regard-
less of the presence or absence of extrapulmonary
ASS-features. The anti-synthetase positive population was
younger at onset and had an almost equal sex ratio.
Nonspecific interstitial pneumonia (NSIP) pattern was
a predominant pathological diagnosis in the anti-synthetase
positive group and the most common HRCT findings were
diffuse ground glass opacities in all lung fields and traction
bronchiectasis in both lower lung fields. Even in cases which
were pathologically diagnosed with UIP, radiographic
features were not typical of IPF/UIP.
The patients with ILD and positive anti-synthetase are in
the category of ASS without myositis. A previous study
Table 3 Summary of clinical manifestations, autoantibody profiles, pathological findings, and fulfillment of criteria of UCTD in












1 54 Fa EJ monoarthritis e þ anti-CCP, SSA fNSIP, lymphoid follicle yes
2 43 M EJ e x40 þ e cNSIP, lymphoid follicle e
3 61 M EJ e x80 e e cNSIP e
4 60 F EJ e x40 e e UIP, cellular infiltrate,
lymphoid follicle
e
5 41 M EJ finger tip hyperkeratosis e e positive ESR, CRP yes
6 62 Ma EJ finger tip eczema,
articular swelling
x40 e anti-CCP yes
7 43 M PL12 fever, body weight loss,
cutaneous manifestation
x40 þ anti-SSA, SSB yes
8 52 M PL12 e x320 þ anti-SSA fNSIP, lymphoid follicle e
9 60 F PL12 e x40 e e UIP, cellular infiltrate,
lymphoid follicle
e
10 54 M Jo-1 finger tip desquamation e e positive CRP yes
11 58 F PL7 sicca e e e fNSIP, lymphoid follicle e
12 45 F OJ Raynaud’s phenomenon e e anti-SSA yes
13 60 F KS e e e e cNSIP, lymphoid follicle e
Abbreviation; ANA Z antinuclear antibody; ESR Z erythrocyte sedimentation rate; CRP Z C-reactive protein; c/f NSIP Z cellular/
fibrosing nonspecific interstitial pneumonia; RFZ rheumatoid factor; UCTDZ undifferentiated connective tissue disease; UIPZ usual
interstitial pneumonia.
a These two cases were retrospectively categorized into early arthritis according to the new ACR/EULAR criteria published in 2010.
These two cases were not classified into RA according to the 1987 ACR criteria. At the study entry, the new ACR/EULAR diagnostic
criteria had not yet been published; therefore we did not exclude these two cases and listed them as anti-synthetase syndrome.
b The criteria of UCTD were by Kinder et al published in 2007.
Antisynthetase syndrome in IIPs 1243showed that anti-synthetase was detected in a proportion
of type 1 diabetes patients21; however another report
showed its 100% specificity to ASS using the IPP method.22 In
this study, no study subject had concurrent type 1 diabetes.
As in previous studies, the prevalence of pulmonary mani-
festation varied among the different antibodies.4,23e26
Anti-Jo-1 is the most prevalent in patients whose
muscular symptoms are obvious, and anti-PL7 and anti-EJ
show the next highest prevalence.3 However, anti-Jo-1 is
less prevalent in patients whose muscular symptoms are
absent or obscure.7,27 Patients with positive anti-PL-12,
anti-KS or anti-OJ tend to have ILD predominantly, rather
than myositis.27e30 In this study, anti-EJ was observed most
frequently in as much as 2.7 percent of patients, while the
prevalence of anti-Jo-1 was small. This result may reflect
the difference in overall frequencies of each antibody
among anti-synthetase positive patients and suggests that
anti-Jo-1 antibody is relatively rare among anti-synthetase
positive patients without myositis.
As to the clinical associations, younger age and increased
CRP or ESRmay be characteristic features of anti-synthetase
positive cases. Among extrapulmonary features of ASS,
arthralgia, joint deformity, or cutaneous symptoms were
significantly observed in anti-synthetase positive cases.
Extrapulmonary features of ASS including Raynaud’s
phenomenon, arthralgia, ormuscular symptomswere absent
in about half of anti-synthetase positive cases; this demon-
strates the difficulty of deciding whether to test for
screening of anti-synthetase based on presence of extrap-
ulmonary symptoms of ASS alone. RF or anti-SSA is often
concomitant in patients with anti-synthetase positive IPs, asreported in previous studies.8,30 Furthermore, it is reported
that coexistence of anti-SSA/Ro and anti-synthetase,
particularly anti-Jo-1, is predictive of a more severe
fibrosis score in HRCT and a reduced treatment response to
immunosuppressants.31,32 Therefore, measurement of
anti-synthetase merits consideration in anti-SSA/Ro positive
cases. Regarding the pulmonary function test results and BAL
fluid findings, predicting the presence of anti-synthetase is
difficult from these practical measurements. All the
anti-synthetase positive cases survived during the study
period; however the observation period was shorter in the
anti-synthetase positive group. Because of the higher
proportion of NSIP in the anti-synthetase positive group,
their survival rate was expected to be better than in those
without the antibody. However, this study did not show
a conclusive difference in survival.
The impact of anti-synthetase on treatment response
and prognosis, especially with common lung histopathology,
needs to be defined in a future study involving a longer
observation period.
The pathological diagnosis in ASS was predominantly
NSIP. Even pathologically confirmed UIP showed some
atypical features (Fig. 3b). Lymphoid follicles were
remarkable findings in the anti-synthetase positive group
(Table 3, Fig. 2c). Lymphoid follicle is commonly seen in
lung biopsy specimens obtained from a case with CTD,
particularly rheumatoid arthritis.33 A recent study demon-
strated that the germinal center score (i.e., number of
lymphoid follicles per microscopic field) was the most dis-
tinguishing feature between CTD-related interstitial pneu-
monia (IP) and IPF/UIP.34 The results of the present study
Figure 2 Pathological images in a patient with positive antibody to aminoacyl-tRNA synthetases (anti-synthetase). Pathological
classification is nonspecific interstitial pneumonia (NSIP). 2-a) Low magnification view shows varying portions of inflammation and
fibrosis distributed uniformly. 2-b) Lung architecture is generally preserved and there is mild to moderate interstitial fibrosis with
cellular infiltrate. 2-c) In the more fibrotic area, the fibrosis is relatively loose. A lymphoid follicle and cellular infiltrate are also
seen (arrow). No honeycombing is seen.
1244 K. Watanabe et al.suggest that lymphoid follicle is characteristic also in anti-
synthetase positive cases.
Chest CT revealed ground glass opacity distributed in all
lung fields, traction bronchiectasis in lower lung fields and
lack of honeycombing, all of which constitute essential
HRCT findings characteristic of a non-UIP pattern. The
HRCT findings of the current study were consistent with
previous reports on interstitial pneumonia associated with
PM/DM.18 Our results were also in agreement with the
American Thoracic Society report on NSIP, which found that
the most consistent HRCT findings of NSIP are reticular
opacities and traction bronchiectasis with lower lung zone
predominance.20 In idiopathic pulmonary fibrosis or idio-
pathic NSIP, centrilobular nodular opacity is not
mentioned1; however in CTD-related lung disease such as
rheumatoid lung disease, nodules are observed in patho-
logical or radiological UIP or NSIP.35 30e40% of such nodules
have been described as exhibiting centrilobular distribu-
tion. Centrilobular nodular opacity may be a finding char-
acteristic of HRCT in anti-synthetase positive IIPs, but
a rigid radio-pathological correlation was not established in
this study.
Some cases with IPs exhibit specific autoantibodies or
CTD signs or symptoms while they do not meet any specificcriteria for CTD. A recent study reported that a large
proportion of patients with idiopathic NSIP fulfilled the
criteria for UCTD.17 Indeed, 6 anti-synthetase positive and
21 anti-synthetase negative patients in our series also ful-
filled the same criteria for UCTD, even without measure-
ment of anti-synthetase. These cases were included in the
study population because some patients with UCTD may be
thought to overlap with ASS. Additionally, diagnostic
criteria have yet to be fully established.36,37 Some rheu-
matologists consider that cases with any disease-specific
autoantibodies, including anti-synthetase, should be
excluded from UCTD.36
Our results suggest that ASS-associated IPs have features
in common with CTD-associated IPs but distinct from other
IIPs, even if clinical CTD symptoms are subtle. Measurement
of anti-synthetase may enable us to pick up such charac-
teristics of otherwise “IIPs” cases, which may comprise
a distinct entity. However, a larger cohort study should be
conducted to address the best classification of such “IIPs”
using certain clinical or serological CTD features.
All the anti-synthetase positive patients in this study
presented with non-UIP pattern on HRCT and the preva-
lence of anti-synthetase antibody was as high as 50% among
histological NSIP or UIP with lymphoid follicles. Thus, anti-
Figure 3 Pathological and radiographic images in a patient with pathological diagnosis of usual interstitial pneumonia (UIP). 3-a)
Low magnification view shows subpleural dense fibrosis and normal alveolar architecture distributed in a patchy manner. 3-b)
Fibrotic area shows temporal heterogeneity and relatively normal alveolar architecture is adjacent to the dense fibrosis. Fibro-
blastic foci are scattered. Mild to moderate cellular infiltrate is also seen. 3-c) Radiographic findings of the CT in lower lung fields
show ground glass opacities, irregular peribronchovascular thickening and traction bronchiectasis, but do not reveal
honeycombing.
Antisynthetase syndrome in IIPs 1245synthetase antibodies should be screened for in patients
with non-UIP pattern on HRCT, or histological NSIP or UIP
with lymphoid follicles. Although all patients with radio-
logically typical UIP in our series were negative for anti-
synthetase antibodies, our results were not conclusive
regarding the significance of screening of these antibodiesTable 4 Frequency of HRCT findings in patients with positive aut





Reticulation 0.63 11 (85)
Ground glass opacity 0.67 8 (62)
Consolidation 0.67 0 (0)
Subpleural lines 0.66 3 (23)







Honeycombing 1.0 0 (0)
a Kappa coefficient of the individual results of two readers.
b Data were expressed as number of patients (percent) judged throin such patients because of the relatively small sample size.
A larger-scale study should be conducted to define the best
candidates for anti-synthetase screening.
Previous reports have shown successful treatment of
corticosteroid-resistant anti-synthetase positive ILD with
immunomodulatory agents such as cyclosporin andoantibodies to aminoacyl-tRNA synthetases (anti-synthetase).
Leftb
middle lower upper middle lower
10 (77) 11 (85) 9 (69) 11 (85) 10 (77)
10 (77) 11 (85) 9 (69) 11 (85) 10 (77)
12 (92) 13 (100) 8 (62) 12 (92) 13 (100)
2 (15) 5 (38) 0 (0) 1 (8) 7 (54)
6 (46) 8 (62) 3 (23) 6 (46) 9 (69)
10 (77) 6 (46) 9 (69) 9 (69) 6 (46)
1 (8) 6 (46) 0 (0) 1 (8) 7 (54)
6 (46) 11 (85) 0 (0) 6 (46) 10 (77)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ugh consensus to have the respective findings.
Figure 4 HRCT findings of centrilobular nodular opacity in an anti-synthetase positive case. Small-size nodules with ground glass
densities are distributed in centrilobules (arrowhead) in the right middle lung (4-a) and in the right lower lung (4-b), respectively.
1246 K. Watanabe et al.tacrolimus.38 Considering the T lymphocyte involvement in
the pathogenesis of ASS,39 different treatment regimensmay
be applied for anti-synthetase positive ILD. In addition, all
anti-synthetase positive cases have survived in the present
study, suggesting that anti-synthetase positive IIPs may have
a better prognosis. Although further examinations are
necessary to confirm these hypotheses, we should stress the
importance of measuring anti-synthetase in IIP for the
identification of specific subgroups.
A limitation to our study was the retrospective study
design.Wecouldnot enroll adequatenumbers ofpatientswho
had obtained a pathological diagnosis of NSIP, to compare
pathological and radiographic features in accordancewith the
anti-synthetase results. We recruited consecutive cases with
IIPs regardless of the presence or absence of lung pathology in
a search for the prevalence and characteristics of the anti-
synthetase positive subpopulation. A large, prospective,
longitudinal cohort of anti-synthetase positive cases would be
required to characterize this clinical entity, incorporating
treatment choice, response and survival.
In conclusion, an anti-synthetase positive subpopulation
was not rare among IIPs. Anti-synthetase should be
screened for in IIP patients, particularly in those with
pathological NSIP or UIP with lymphoid follicles, even if no
suggestive extrapulmonary manifestation exists.Acknowledgements
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